Oraxion Therapeutics, a spin-off from BIRAC supported Aten Porus Lifesciences has entered into an "Option to License" agreement for US $125 Million with a US-based biopharma company to licence its drug ORX-301 for the treatment of rare diseases
https://www.biovoicenews.com/indian-startup-develops-drug-for-key-orphan-diseases-partners-us-firm/
http://www.prweb.com/releases/2018/02/prweb15153457.htm
© 2019 B I R A C